Pharmaceutical Company-Sponsored Studies

The following pharmaceutical company-sponsored studies are active or pending:

 

Oxo Chemie WF-10 Protocol: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients with Late-Stage HIV Disease

 

Merck 019: A Multiclinic, Double-Blind, Randomized Twenty-Four Week Study to Compare the Safety, Tolerability, and Biologic Activity of MK-0639 and Zidovudine Administered Concomitantly to MK-0639 Alone and Zidovudine Alone in HIV-1 Seropositive Patients - Open Label Extension

 

Merck 075: A Multicenter, Open-label Study of the Effect of Indinavir, Efavirenz and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir (075-00)

 

Merck 008: A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 mg b.i.d., in Combination with Two nRTIs in HIV-1-Infected Patients who Failed an Indinavir Containing Regimen

 

Agouron AG1549: A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination with Viracept and Combivir in Treatment-Naive HIV-1-infected Patients

 

Gilead GS-99-907: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Tenofovir Disoproxil Fumarate in Combination with other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients

 

            In addition, the Hawaii AIDS Research Program has been selected as a site for phase III testing of a recombinant HIV-1 gp120 env gene vaccine (VaxGen VAX004:  A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults At Risk of Sexually Transmitted HIV-1 Infection in North America).

 

Back to PROJECTS